Prospects of Future Typhoid and Paratyphoid Vaccines in Endemic Countries.
Where this comes from
- Record sourced from PubMed, PMID 34374785.
- Also identified by DOI 10.1093/infdis/jiab393 and PMC identifier 8687069.
- Licence recorded as CC BY.
- The licence permits redistribution, so the abstract is shown in full and the full text is available from the publisher.
Abstract
Low- and middle-income countries face a high burden of typhoid and paratyphoid fever due to poor water quality and inadequate sanitation. The World Health Organization (WHO) recommends the use of typhoid conjugate vaccines (TCV) in endemic settings and Gavi, the Vaccine Alliance, supports TCV introduction. There are currently 2 WHO-prequalified TCVs with Typbar TCV introduced in Pakistan, Liberia, and Zimbabwe. Countries should assess disease burden and consider introduction of TCV for programmatic use. Several paratyphoid vaccine candidates are in early stages of development. An effective bivalent vaccine would be the most efficient way to control typhoid and paratyphoid fever.
Medical subject headings
- Paratyphoid Fever
- Typhoid Fever
- Typhoid-Paratyphoid Vaccines
- Vaccines, Conjugate